CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)
NCT: NCT03263494 · COMPLETED
Brief Summary
Adolescents and young adults with T1D and poor glycemic control (age 14-\< 25 years, T1D duration \>12 months, HbA1c 7.5-\<11.0%, using an insulin pump or MDI)) will be randomly assigned to either CGM or BGM. Sample size will be 150. The primary outcome assessment will be HbA1c after 6 months. Secondary outcomes will include HbA1c, CGM metrics (control group will wear blinded CGM at 13 and 24 weeks), and quality of life measures. The randomized trial will be followed by a 6-month extension study during which the RCT control group will initiate CGM and the RCT CGM group will continue CGM.
Frequently Asked Questions
What is CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)?
CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D) is a clinical trial registered under NCT03263494. Current status: COMPLETED.
What is the status of NCT03263494?
The current status of NCT03263494 (CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)) is: COMPLETED.
When did CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D) start?
CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D) started on 2018-01-25.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.